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Abstract
Background: The Romanian HIV cohort has certain particularities that render it unique in Europe. We have
performed a study to evaluate the prevalence of bone and kidney impairment in this particular group of HIV-
infected patients.
Methods: We performed dual-energy X-ray absorptiometry (DXA) evaluation of the lumbar vertebrae and the
femur, as well as laboratory tests including standard serum panels, bone-related markers and urinalysis in patients
from the Romanian HIV cohort.
Results: The study included 72 patients, of which 46 (58.3 %) were males. The median (IQR) age was 38 (18) years
and the median (IQR) time from HIV infection diagnosis was 9 (13) years. Most patients (55.6 %) were non-smokers,
but a relatively high proportion (37.5 %) was currently smoking. Only a small percentage of patients (20.8 %) did
not present any comorbidities, while 40.3 % had one comorbidity, the most frequent being dyslipidemia (present in
25 patients, 38.5 %). Only 6 patients had a medical history suggestive for renal disease and 3 for bone-related
abnormalities.
The median (IQR) glomerular filtration rate was 97.5 (33.0) mL/min/1.73sqm. We diagnosed 21 patients (29.6 %) with
stage 2 chronic kidney disease and one patient (1.4 %) with stage 3 chronic kidney disease. Proteinuria was present
in 9 (12.7 %) patients. The estimated glomerular filtration rate was significantly lower in patients with cardiac
comorbidities (p = 0.013).
Vitamin D was significantly lower in smokers compared with non-smokers, with a mean value of 15 vs. 21 ng/mL
and a moderate effect size (Cohen’s d = −0.5) (p = 0.046). Lumbar osteopenia and osteoporosis were diagnosed in
33.3 and 13.7 % of patients, while femoral osteopenia and osteoporosis were diagnosed in 37.3 and 7.8 %,
respectively. Lower nadir CD4 cell counts were found in patients with bone-related comorbidities (p = 0.000).
Conclusions: We identified a relatively high prevalence of chronic kidney disease in the Romanian HIV cohort, and
a fairly low prevalence of osteopenia and osteoporosis, compared with other European countries. In this category
of patients smoking should be avoided altogether, as it may be an indirect risk factor for kidney disease (associating
cardiac comorbidities) and it may impair bone metabolism by altering serum levels of hydroxy-vitamin D.
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Background
The Romanian HIV cohort has certain particularities that
render it unique in Europe. The circulating HIV strains
belong mainly to clade F and infection was acquired at an
early age, in infancy and childhood, in the late ‘80s [1].
Therefore, patients from the Romanian cohort have seen
antiretroviral (ARV) drugs come and go, and they have
tried all available therapeutic options, even before the
HAART era, when combination therapy had not yet been
deemed as standard of care [2].
Given this unique background, and the patients’ his-
tory of over 20 years of HIV infection [3], we performed
a study to check for renal impairment and bone
demineralization in patients monitored for HIV infection
in one Romanian HIV reference center in Bucharest [4],
in order to design individualized therapeutic approaches
and updated guidelines for screening and management
in this particular patient population [5, 6].
Methods
We performed a cross-sectional study in patients from
the Romanian HIV cohort, to evaluate renal function
through urinalysis, serum creatinine, serum urea, cre-
atinine clearance and estimated glomerular filtration rate
(eGFR), calculated using the Modification of Diet in
Renal Disease (MDRD) formula [7]. Renal stiffness was
assessed by one trained operator through shear-waves
elastography on Aixplorer (SuperSonic Imagine, Aix-en-
Provence, France). The bone was evaluated through
dual-energy X-ray absorptiometry (DXA) scan of the
lumbar vertebrae and the left femur. Bone-related
markers such as serum hydroxy-vitamin D and parathy-
roid hormone levels were also quantified. Serum calcium
levels but not serum phosphorus levels were assessed.
The Romanian HIV cohort currently includes 13 536
patients (data current through 30 September 2015) [8],
from a total of 20 968 patients diagnosed and monitored
between 1985 and 2015. Of these, approximately 2200
are under active surveillance in the National Institute for
Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, and
72 patients presented for evaluation and accepted to par-
ticipate in this study between January 2015 and August
2015.
Prior to inclusion in the study, all patients signed a
written informed consent form. The study protocol was
approved by the local Ethics Committee.
Statistical analysis was performed with SPSS Statistics
for Windows (version 22.0, IBM Corp, Armonk, NY,
USA). The descriptive analysis presents the mean and
standard deviation (SD) for normally-distributed data or
the median and interquartile range (IQR) values for
non-normally-distributed data. The statistical analysis
reports the independent-samples t test with effect size
calculation for normally-distributed variables, and the
Mann-Whitney U non-parametric test for independent
samples, for non-normally-distributed variables. P values
were considered statistically significant when < 0.05.
Results
The study included 72 patients, of which 46 (58.3 %)
were males. The median (IQR) age was 38 (18) years
and the median (IQR) time from HIV infection diagnosis
was 9 (13) years. Patient characteristics are presented in
Table 1. The mean ± SD weight and height were 71 ±
15.3 kg and 171 ± 9.8 cm, respectively, with a mean ± SD
body mass index of 23.7 ± 3.7 kg/sqm. At the time of
evaluation, most of the patients had received one prior
ARV regimen (31.9 %) or over three prior regimens
(30.6 %), while only 3 subjects were at their first treatment
regimen (4.2 %). Most patients (54.2 %) had detectable
and quantifiable HIV viral loads, while only 38.9 % had
undetectable HIV viral loads. The median (IQR) current
CD4 cell count was 508 (380) cells/cmm, with a nadir
count of 387 (290) cells/cmm, in the range of 19–1190
cells/cmm.
Most patients (55.6 %) were non-smokers, but a rela-
tively high proportion (37.5 %) was currently smoking.
Only a small percentage of patients (20.8 %) did not
present any comorbidities, while 40.3 % had one comor-
bidity, the most frequent being dyslipidemia (present in
25 patients, 38.5 %). Thirteen patients (18.1 %) had 2
comorbidities, 2 patients (2.8 %) displayed 3 comorbidi-
ties and 5 patients (6.9 %) had 4 comorbidities. Import-
antly, only 6 patients had a medical history suggestive
for renal disease: renal cyst (n = 3), renal angiomyoli-
poma (n = 1), renal lithiasis (n = 2), and hydronephrosis
(n = 1). Interestingly, of these 6 patients 4 had normal
eGFR (and negative proteinuria), while the other two
patients presented stage 1 and 3 chronic kidney disease,
respectively. Three patients had positive medical history
for bone-related abnormalities (herniated lumbar disc,
bilateral coxarthrosis, and rheumatoid arthritis, respect-
ively). Of these, two had insufficient serum levels of
hydroxy-vitamin D, abnormal (high/low) parathyroid
hormone levels but normal bone mineralization, while
the third patient had normal serum levels of hydroxy-
vitamin D and parathyroid hormone but was diagnosed
with femoral osteopenia.
One patient refused to undergo urinalysis or serum
screening for kidney function. For the rest of the
patients, the median (IQR) eGFR estimated by MDRD
was 108.4 (34.7) mL/min/1.73sqm (Table 2). Based on our
screening procedures, 21 patients (29.6 %) were diagnosed
with stage 2 chronic kidney disease (with a mild decrease
in eGFR, in the range of 60–89.9 mL/min/1.73 sqm) and
one patient (1.4 %) with stage 3 chronic kidney disease
(eGFR of 59.5 mL/min/1.73 sqm). Proteinuria was present
in only 9 (12.7 %) of patients.
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The eGFR did not differ significantly with gender (p =
0.523), smoking status (p = 0.109), number of comorbidi-
ties (p = 0.387), presence of bone-related comorbidities
(p = 0.871), kidney (p = 0.290), metabolic (p = 0.160) or
hemato-oncologic comorbidities (p = 0.541). However,
eGFR was significantly lower in patients with cardiac
comorbidities (p = 0.013, U = 52).
Bone-related markers were measured for 63 patients
who consented to the blood tests. Hypoparathyroidism was
diagnosed in 7.9 % of patients, and hyperparathyroidism in
33.3 %. Most patients (65.1 %) had insufficient serum levels
of hydroxy-vitamin D, and 25.4 % had hydroxy-vitamin D
deficiency (Table 3). Notably, screening was performed
during spring and summer. Vitamin D was significantly
lower in smokers compared with non-smokers, with a
mean value of 15 vs. 21 ng/mL and a moderate effect size
(Cohen’s d = −0.5) (p = 0.046).
DXA scans were performed in 51 patients; the rest
of the patients did not consent to the scan. Almost
half (45.1 %) of the results were suggestive for normal
Table 1 Patient characteristics
Characteristic Sub-category n (%) Median (IQR) Percentiles 25, 75
Male gender 46 (58.3)
Age, years 38 (18) 26, 44
Time since HIV diagnosis, years 9 (13) 4, 17











Current CD4 cell count, cells/cmm 508 (380) 289, 669
Nadir CD4 cell count, cells/cmm 387 (290) 229, 519
Current viral load, copies/mL Undetectable 28 (38.9)
Below LLQa 5 (6.9)
Detectable (range: 27 to 170,000,000) 39 (54.2) 5617 (95224) 37.5, 95261
Smoking status Ex-smokerb 2 (2.8)
Current-smoker 27 (37.5)
Non-smoker 40 (55.6)
Refused to declare 3 (4.2)










ARV antiretroviral, IQR interquartile range, LLQ lower limit of quantitation
aHIV-RNA TaqMan – limit of detection of 20 copies/mL
bEx-smokers were defined as having completely quit smoking for over 6 months
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bone mineral density, but a high proportion of pa-
tients already displayed osteopenia (33.3 % with lum-
bar and 37.3 % with femoral localization).
Furthermore, lumbar osteoporosis was diagnosed in
13.7 % of patients (with ages of 26, 30, 33, 38, 40, 47
and 65 years) and femoral osteoporosis in 7.8 % of
patients (with ages of 26, 40, 44, 50 years).
Lumbar or femoral T-scores did not differ significantly
with gender (p = 0.850 and p = 0.961, respectively), num-
ber of comorbidities (p = 0.168 and p = 0.126, respect-
ively), presence of bone-related comorbidities (p = 0.933
and p = 0.826, respectively), kidney (p = 0.489 and p =
0.750, respectively), metabolic (p = 0.291 and p = 0.394,
respectively), cardiac (p = 0.828 and p = 0.343, respect-
ively) or hemato-oncologic comorbidities (p = 0.306 and
p = 0.618, respectively).
We identified a statistical association between bone-
related comorbidities and nadir CD4 cell count, pa-
tients with this type of comorbidities having lower
mean nadir CD4 cell counts (150 vs. 406 cells/cmm),
with a large effect size (Cohen’s d = −1.5). No other
statistical associations were found between other types
Table 2 Kidney function tests results for patients screened in this study (n = 71)
Characteristic Sub-category n (%) Median (IQR) Percentiles 25, 75 Mean ± SD
Serum urea, mg/dL N/A N/A 30.2 ± 8.5
Serum creatinine, mg/dL 0.8 (0.3) 0.7, 1.0 N/A
eGFR, mL/min/1.73 sqm 108.4 (34.7) 89.5, 124.2 N/A
eGFR Stage 1 > 90 49 (69.0)
Stage 2 60–89.9 21 (29.6)
Stage 3 30–59.9 1 (1.4)
Stage 4 15–29.9 0 (0)
Stage 5 < 15 0 (0)
Positive proteinuria, n (%) 9 (12.7)
Renal elastography, kPa 17.1 (11) 12.4, 23.4 N/A
eGFR estimated glomerular filtration rate, IQR interquartile range, N/A not applicable, SD standard deviation
eGFR was calculated by MDRD [7] and is expressed in mL/min/1.73 sqm. Renal stiffness was assessed for 19 patients by one trained operator through shear-waves
elastography on Aixplorer (SuperSonic Imagine, Aix-en-Provence, France)
Table 3 Bone-related tests results for patients screened in this study
Characteristic Sub-category n (%) Median (IQR) Percentiles 25, 75 Mean ± SD
DXA scan result (n = 51) Normal bone mineral density 23 (45.1)
Lumbar osteopenia 17 (33.3)
Lumbar osteoporosis 7 (13.7)
Femoral osteopenia 19 (37.3)
Femoral osteoporosis 4 (7.8)
Lumbar L1-L4 DXA T-score N/A N/A –0.8 ± 1.0
Left femur DXA T-score N/A N/A –0.4 ± 0.8
Serum parathyroid hormone, pg/mL 48.2 (43.6) 27.7, 71.3 N/A
Interpretation of serum parathyroid hormone (n = 63) Decreased (<15 pg/mL) 5 (7.9)
Normal (15–65 pg/mL) 37 (58.7)
Increased (>65 pg/mL) 21 (33.3)
Serum hydroxy-vitamin D, ng/mL N/A N/A 18.8 ± 10.8
Interpretation of serum hydroxy-vitamin D levels (n = 63) Deficient (<10 ng/mL) 16 (25.4)
Insufficient (10–29.9 ng/mL) 41 (65.1)
Optimal (30–99.9 ng/mL) 6 (9.5)
Toxic (>100 ng/mL) 0 (0)
IQR interquartile range, N/A not applicable, SD standard deviation
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of comorbidities and current or nadir CD4 cell count,
HIV viral load, renal stiffness, hydroxy-vitamin D or
parathyroid hormone (Table 4).
Discussion
Our study has described the epidemiology of chronic
kidney disease and bone demineralization in HIV-
positive patients from the Romanian HIV cohort. In
this study 29.6 % of patients were diagnosed with
stage 2 kidney disease and 1.4 % with stage 3 kidney
disease. These numbers are quite high, compared with
a prevalence of chronic kidney disease in patients
with HIV infection reported at 6 % in the Danish
HIV cohort study [9], 24 % in Nigeria [10], and 2 %
[11], 10.2 % [12] or 15.5 % [13] in the United States
of America.
We have also identified that cardiac comorbidities
are risk factors for kidney disease in HIV-positive pa-
tients from our cohort (p = 0.013). Other similar stud-
ies also report hypertension as a risk factor for
additional kidney damage in HIV-positive patients
[11] compared with the HIV-negative population.
Smoking has not been identified as a direct risk fac-
tor for renal disease (p = 0.109), our results being in
line with data reported from other European coun-
tries, for example the Danish HIV cohort study [9];
however, given the recognized correlation between
smoking and cardiovascular disease and our study’s
findings that cardiac comorbidities associate a de-
creased eGFR, we suggest that HIV-positive patients
who are current smokers should also be monitored
for renal function. Moreover, as our study has shown
that smoking is associated with significantly lower
levels of hydroxy-vitamin D, this points to the fact
that smoking should be avoided altogether by HIV-
positive patients, as it not only targets the kidney, but
the bone metabolism as well.
Lumbar osteopenia and osteoporosis were diagnosed
in 33.3 and 13.7 % of patients, respectively; femoral
osteopenia and osteoporosis were diagnosed in 37.3 and
7.8 %, respectively. Notably, the median age in this study
was 38 years (IQR: 18 years), suggesting that this high
prevalence of bone and kidney disease is rather corre-
lated with the long evolution of HIV infection (median:
9 years, IQR: 13 years) than with patient age. These
results are, to an extent, encouraging, as other studies
report a higher prevalence of osteopenia or osteoporosis
in HIV-positive patients, i.e., 51 and 10 %, respectively,
in the United States of America [14], 63.2 and 15.1 % in
Italy [15], and 56.5 and 10.7 % in Spain [16]. However,
studies from Brazil report a much lower prevalence of
decreased bone mineral density in patients with HIV
infection, i.e. 14.6 % in the lumbar vertebrae and 5.6 %
in the femur [17].
We also found lower nadir CD4 cell counts in patients
with bone-related comorbidities (p = 0.000). A recent
study from Australia defined a series of risk factors for
low bone mineral density in treatment-naïve HIV-
positive patients, and they found no association with
nadir CD4 cell count [18]. However, seeing as that study
was performed in patients with mean nadir CD4 cell
counts above 500 cells/cmm, who had not yet met any
criteria for starting ARV treatment, we expect their data
to be significantly different from that derived from our
study, where most patients were under ARV treatment,
and the nadir CD4 cell count was 387 cells/cmm. Our
finding that lower nadir CD4 cell counts are associated
with bone-related abnormalities confirm previous stud-
ies performed in Spain, which reported lower bone min-
eral density in patients with lower nadir CD4 cell count
[16].
Conclusions
We identified a relatively high prevalence of chronic kid-
ney disease in the Romanian HIV cohort, and a fairly
low prevalence of osteopenia and osteoporosis, com-
pared with other European countries. Lower nadir CD4
cell counts were statistically correlated with the presence
of bone-related comorbidities. In this category of pa-
tients smoking should be avoided altogether, as it may
be an indirect risk factor for kidney disease (associating
cardiac comorbidities) and it may impair bone metabol-
ism by altering serum levels of hydroxy-vitamin D.

















Cardiac 0.472 0.685 0.321 0.443 0.910 0.053 0.052
Metabolic 0.136 0.774 0.326 0.553 0.579 0.091 0.090
Renal 0.275 0.362 0.321 N/Aa 0.365 0.532 1.000
Bone-related 0.969 0.000 0.326 0.443 0.500 0.613 0.324
Hemato-oncologic 0.551 0.818 0.321 0.773 0.601 0.695 1.000
P values are reported. Statistically-significant results are marked in bold
Renal stiffness was assessed for 19 patients by one trained operator through shear-waves elastography on Aixplorer (SuperSonic Imagine, Aix-en-Provence, France)
aRenal stiffness could not be evaluated in patients with pre-existing kidney comorbidities
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